Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland

被引:20
|
作者
Grosse, Alexandra [1 ]
Grosse, Claudia [2 ]
Rechsteiner, Markus [3 ]
Soltermann, Alex [1 ]
机构
[1] Univ Hosp Zurich, Inst Pathol & Mol Pathol, Clin Pathol, Ramistr 100, CH-8091 Zurich, Switzerland
[2] Kepler Univ Hosp, Inst Pathol, Krankenhausstr 9, A-4021 Linz, Austria
[3] Univ Hosp Zurich, Inst Pathol & Mol Pathol, Diagnost Mol Pathol, Ramistr 100, CH-8091 Zurich, Switzerland
关键词
Lung adenocarcinoma; EGFR; KRAS; ALK; RET; ROS1; BRAF; ERBB2; MET; PIK3CA; Non-small cell lung cancer; EML4-ALK FUSION GENE; KRAS MUTATIONS; CLINICAL CHARACTERISTICS; CANCER PATIENTS; EGFR; PIK3CA; MET; SPECTRUM; DOMAIN; TUMOR;
D O I
10.1186/s13000-019-0789-1
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
BackgroundMolecular testing of lung adenocarcinoma for oncogenic driver mutations has become standard in pathology practice. The aim of the study was to analyze the EGFR, KRAS, ALK, RET, ROS1, BRAF, ERBB2, MET and PIK3CA mutational status in a representative cohort of Swiss patients with lung adenocarcinoma and to correlate the mutational status with clinicopathological patient characteristics.MethodsAll patients who underwent molecular testing of newly diagnosed lung adenocarcinoma during a 4-year period (2014-2018) were included. Molecular analyses were performed with Sanger sequencing (n=158) and next generation sequencing (n=311). ALK, ROS1 and RET fusion gene analyses were also performed with fluorescence in situ hybridization and immunohistochemistry/immunocytochemistry. Demographic and clinical data were obtained from the medical records.ResultsOf 469 patients with informative EGFR mutation analyses, 90 (19.2%) had EGFR mutations. KRAS mutations were present in 33.9% of the patients, while 6.0% of patients showed ALK rearrangement. BRAF, ERBB2, MET and PIK3CA mutations and ROS1 and RET rearrangements were found in 2.6%, 1.9%, 1.9%, 1.5%, 1.7% and 0.8% of the patients, respectively. EGFR mutation was significantly associated with female gender and never smoking status. ALK translocations were more frequent in never smokers, while KRAS mutations were more commonly found in ever smokers. The association between KRAS mutational status and female gender was statistically significant only on multivariate analysis after adjusting for smoking.ConclusionThe EGFR mutation rate in the current study is among the higher previously reported mutation rates, while the frequencies of KRAS, BRAF, ERBB2 and PIK3CA mutations and ALK, ROS1 and RET rearrangements are similar to the results of previous reports. EGFR and KRAS mutations were significantly associated with gender and smoking. ALK rearrangements showed a significant association with smoking status alone.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland
    Alexandra Grosse
    Claudia Grosse
    Markus Rechsteiner
    Alex Soltermann
    Diagnostic Pathology, 14
  • [2] Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome
    Grosse, Claudia
    Soltermann, Alex
    Rechsteiner, Markus
    Grosse, Alexandra
    PLOS ONE, 2019, 14 (08):
  • [3] Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma
    Difan Zheng
    Rui Wang
    Yunjian Pan
    Shanbo Zheng
    Yang Zhang
    Hang Li
    Chao Cheng
    Ranxia Gong
    Yuan Li
    Xuxia Shen
    Haichuan Hu
    Deng Cai
    Xinghua Cheng
    Yihua Sun
    Haiquan Chen
    Annals of Surgical Oncology, 2015, 22 : 1284 - 1291
  • [4] Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma
    Zheng, Difan
    Wang, Rui
    Pan, Yunjian
    Zheng, Shanbo
    Zhang, Yang
    Li, Hang
    Cheng, Chao
    Gong, Ranxia
    Li, Yuan
    Shen, Xuxia
    Hu, Haichuan
    Cai, Deng
    Cheng, Xinghua
    Sun, Yihua
    Chen, Haiquan
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S1284 - S1291
  • [5] Analysis of CDK4/6 Pathway Activity in Lung Adenocarcinoma Patients with Oncogenic Driver Mutations in China
    Yu, Y.
    Lu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S812 - S813
  • [6] Clinicopathological characteristics of lung adenocarcinoma with EGFR compound mutations
    Hayashi, Takuo
    Kohsaka, Shinji
    Takamochi, Kazuya
    Hara, Kieko
    Takahashi, Fumiyuki
    Suehara, Yoshiyuki
    Saito, Tsuyoshi
    Suzuki, Kenji
    Mano, Hiroyuki
    Yao, Takashi
    MODERN PATHOLOGY, 2019, 32
  • [7] Clinicopathological characteristics of lung adenocarcinoma with compound EGFR mutations
    Hayashi, Takuo
    Kohsaka, Shinji
    Takamochi, Kazuya
    Hara, Kieko
    Kishikawa, Satsuki
    Sano, Kei
    Takahashi, Fumiyuki
    Suehara, Yoshiyuki
    Saito, Tsuyoshi
    Takahashi, Kazuhisa
    Suzuki, Kenji
    Yao, Takashi
    HUMAN PATHOLOGY, 2020, 103 : 42 - 51
  • [8] Clinicopathological characteristics of lung adenocarcinoma with EGFR compound mutations
    Hayashi, Takuo
    Kohsaka, Shinji
    Takamochi, Kazuya
    Hara, Kieko
    Takahashi, Fumiyuki
    Suehara, Yoshiyuki
    Saito, Tsuyoshi
    Suzuki, Kenji
    Mano, Hiroyuki
    Yao, Takashi
    LABORATORY INVESTIGATION, 2019, 99
  • [9] Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma
    Zhou, Xiuzhi
    Cai, Li
    Liu, Junjie
    Hua, Xiaomin
    Zhang, Ying
    Zhao, Huilin
    Wang, Bin
    Li, Boqing
    Gai, Pengzhou
    ONCOLOGY LETTERS, 2018, 16 (01) : 362 - 370
  • [10] Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma
    De Maio, Andrew
    Clarke, Jeffrey M.
    Dash, Rajesh
    Sebastian, Siby
    Wahidi, Momen M.
    Shofer, Scott L.
    Cheng, George Z.
    Li, Xuechan
    Wang, Xiaofei
    Mahmood, Kamran
    JOURNAL OF BRONCHOLOGY & INTERVENTIONAL PULMONOLOGY, 2019, 26 (02) : 96 - 101